Nikolaus Zacherl
Directeur/Bestuurslid bij Avir Green Hills Biotechnology AG
Profiel
Nikolaus Zacherl is the founder of ORIDIS Biomed Forschungs & Entwicklungs GmbH, which was founded in 2001.
He is currently a Director-Supervisory Board at Avir Green Hills Biotechnology AG.
In the past, he worked as a Principal at Novartis AG and Research Institute of Molecular Pathology.
Actieve functies van Nikolaus Zacherl
Bedrijven | Functie | Begin |
---|---|---|
Avir Green Hills Biotechnology AG
Avir Green Hills Biotechnology AG Medical SpecialtiesHealth Technology AVIR Green Hills Biotechnology is a biopharmaceutical company based in Vienna, Austria. The company uses its know-how in virology to develop and commercialize innovative products that offer cost-effective treatment for a wide range of diseases. The products under development by AVIR Green Hills Biotechnology are unique therapies against viral infectious diseases and cancer with the aim to significantly improve health and the quality of life of human beings. In exploratory research and product development, AVIR Green Hills Biotechnology is closely cooperating with national and international academic institutions and Clinics, among them include the Clinics of the Medical University Vienna, and the Institute for Medical Virology at Goethe-University Frankfurt am Main. For clinical trials, the firm collaborates with experienced and renowned institutions, such as the General Hospital Vienna. For phase III clinical trials, regulatory approval, marketing and sales it will seek strategic partnerships and cooperation's with pharmaceutical or biotechnological companies. | Directeur/Bestuurslid | 17-09-2009 |
Eerdere bekende functies van Nikolaus Zacherl
Bedrijven | Functie | Einde |
---|---|---|
Research Institute of Molecular Pathology | Corporate Officer/Principal | - |
ORIDIS Biomed Forschungs & Entwicklungs GmbH
ORIDIS Biomed Forschungs & Entwicklungs GmbH Medical SpecialtiesHealth Technology ORIDIS Biomed - a specialist in tissue-based cancer research - is a Contract Research Organization founded in 2001 as a spin-off from the Medical University of Graz. Based on its unique clinical and biobank network and its sound molecular pathological expertise ORIDIS Biomed designs and performs retrospective and prospective customized tissue- and body fluid- based studies. The company brings value to its customers by evaluation of the medical and clinical relevance of drug targets, mode-of-action models and biomarker candidates for patient stratification and diagnosis. ORIDIS Biomed's unique offering combines its proprietary TISSOMIC research platform and proven experience in analysis of clinically relevant tissue with access to a biobank with 2.9 million samples of diseased human tissue and associated data. Research activities at ORIDIS Biomed are focused on the validation and development of tissue- and blood-based nucleic acid biomarkers for early cancer diagnosis, patient stratification and therapy monitoring. | Oprichter | - |
NOVARTIS AG | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
NOVARTIS AG | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
ORIDIS Biomed Forschungs & Entwicklungs GmbH
ORIDIS Biomed Forschungs & Entwicklungs GmbH Medical SpecialtiesHealth Technology ORIDIS Biomed - a specialist in tissue-based cancer research - is a Contract Research Organization founded in 2001 as a spin-off from the Medical University of Graz. Based on its unique clinical and biobank network and its sound molecular pathological expertise ORIDIS Biomed designs and performs retrospective and prospective customized tissue- and body fluid- based studies. The company brings value to its customers by evaluation of the medical and clinical relevance of drug targets, mode-of-action models and biomarker candidates for patient stratification and diagnosis. ORIDIS Biomed's unique offering combines its proprietary TISSOMIC research platform and proven experience in analysis of clinically relevant tissue with access to a biobank with 2.9 million samples of diseased human tissue and associated data. Research activities at ORIDIS Biomed are focused on the validation and development of tissue- and blood-based nucleic acid biomarkers for early cancer diagnosis, patient stratification and therapy monitoring. | Health Technology |
Avir Green Hills Biotechnology AG
Avir Green Hills Biotechnology AG Medical SpecialtiesHealth Technology AVIR Green Hills Biotechnology is a biopharmaceutical company based in Vienna, Austria. The company uses its know-how in virology to develop and commercialize innovative products that offer cost-effective treatment for a wide range of diseases. The products under development by AVIR Green Hills Biotechnology are unique therapies against viral infectious diseases and cancer with the aim to significantly improve health and the quality of life of human beings. In exploratory research and product development, AVIR Green Hills Biotechnology is closely cooperating with national and international academic institutions and Clinics, among them include the Clinics of the Medical University Vienna, and the Institute for Medical Virology at Goethe-University Frankfurt am Main. For clinical trials, the firm collaborates with experienced and renowned institutions, such as the General Hospital Vienna. For phase III clinical trials, regulatory approval, marketing and sales it will seek strategic partnerships and cooperation's with pharmaceutical or biotechnological companies. | Health Technology |
Research Institute of Molecular Pathology |